Navigation Links
New Chronic Wound Therapy Awarded at Texas' Largest Life Science Event
Date:5/24/2012

SAN ANTONIO, May 24, 2012 /PRNewswire-iReach/ -- An advisory board of industry leaders at the 2012 Texas Life Science Venture Forum in Houston, Texas namedTransCU O2®, a cutting-edge therapy for chronic wounds, one of ten Most Promising Life Science Technologies.  Over 60 companies were invited to present their research and innovations to hundreds of early-stage investors, venture capitalists, and industry leaders.

This award represents another important achievement for Electrochemical Oxygen Concepts (EO2), the maker of the TransCU O2®.  The company has also recently received recognition by the Department of Veterans Affairs.  EO2 CEO Michael Wells says he and his team are honored by the accolades.

"Patients suffering from chronic wounds and their physicians have long been in need of a better therapy to treat their condition," said Wells. "This award from the Texas Life Science Venture Forum further confirms that TransCU O2® is a ground breaking therapy with the ability to improve the health and lives of patients who suffer with difficult-to heal wounds."

The TransCU O2® is a simple-to-use and easy-to-administer therapy that provides a continuous supply of low-dose pure oxygen to treat a variety of wound types such as venous leg ulcers, diabetic foot ulcers, and pressure ulcers.  Oxygen-based therapies have been proven effective in treating chronic wounds but current therapeutic approaches do not allow for 24-hour a day wound treatment.  The TransCU O2® device is lightweight and fully portable.  Its advanced technology allows for the constant monitoring and automatic flow adjustments necessary for the delivery of optimum therapeutic oxygen flow to the wound site.

The Texas Life Science Venture Forum is a joint effort between the Rice Alliance of Technology and Entrepreneurship, BioHouston, and the Texas Healthcare and BioScience Institute and part of the three-day Texas Life Science Conference.  The conference is the most comprehensive showcase of cutting-edge research and innovative entrepreneurs in the state.  Hundreds of investors, entrepreneurs, successful business people and industry leaders attended to learn about, evaluate and network with the presenting companies.

About Electrochemical Oxygen Concepts (EO2™ Concepts):
EO2™ Concepts is a privately held advanced wound care technology company and the developer of an innovative FDA cleared Class III medical device that provides therapy to difficult-to-heal wounds.  The TransCu O2® is an electrochemical low-dose tissue oxygenation and wound monitoring system designed for use with advanced wound dressings as an adjunctive therapy to treat oxygen compromised wounds.  TransCU O2® is a registered trade mark of Electrochemical Oxygen Concepts.  For more information, please visit www.eo2concepts.com.  

Media Contact: Megan Augustine Megan Augustine, 210-296-9520, mg.augustine@gmail.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Electrochemical Oxygen Concepts
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
3. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
4. Researchers Report First Successful Treatment of Chronic Traumatic Brain Injury
5. R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
6. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
9. Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
10. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
11. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... PALO ALTO, Calif. , Feb. 8, 2016 ... chemical manufacturing, and Kodiak Sciences Inc., a biopharmaceutical company ... retinal disease, announced today agreements for the clinical supply ... manufacture material at multiple sites, including Slough (UK), Visp ... --> Retinal diseases, such as age-related ...
(Date:2/8/2016)... N.C. , Feb. 8, 2016  Avista Pharma ... Eric Setzer as Chief Financial Officer (CFO). Mr. ... twenty years of experience in various roles within growing ... Pharma, he served as the Executive Director of Finance ... in Raleigh, NC . Previously, Mr. ...
(Date:2/8/2016)... Vestagen Technical Textiles, Inc., a medical technology ... and other demanding applications, today announced it has named ... Dale Pfost , PhD, who was serving as ... joining Vestagen,s Board of Directors. ® , ... technologies that combines fluid repellent, antimicrobial and breathability properties. ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that your ... are not alone. According to the Center for Disease Control and Prevention (CDC), 34.9% ... diabetes and certain types of cancer, some of the leading causes of preventable death. ...
(Date:2/8/2016)... ... February 08, 2016 , ... Steve Helwig & Associates Insurance & ... community enrichment program, has teamed up with Citizens Opposed to Domestic Abuse in support ... abuse. To support all those victimized by the fear of violence in their own ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... serving the greater Venice, FL area, has initiated a fundraiser for a two ... accident just four days after Christmas. To support this beautiful child who is ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... firm, announced today that nominations will be accepted February 8, 2016 through ... , Awards include the Information Security Executive® of the Year, which ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and post-traumatic stress ... women and men with eating disorders report a history of trauma, research suggests ... of an eating disorder. , At the 2016 iaedp Symposium, the workshop, ...
Breaking Medicine News(10 mins):